Enterprise Value
167.2B
Cash
34.25B
Avg Qtr Burn
N/A
Short % of Float
1.19%
Insider Ownership
0.24%
Institutional Own.
79.33%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BLINCYTO® (blinatumomab) Details B-cell acute lymphoblastic leukemia | Approved Quarterly sales | |
Uplizna® (inebilizumab-cdon) Details Inflammatory disease | Approved Quarterly sales | |
TAVNEOS (Avacopan) (C5aR) Details ANCA-Associated Vasculitis, Autoimmune disease | Approved Quarterly sales | |
TEPEZZA Details Eye disease , Thyroid Eye Disease | Approved Quarterly sales | |
KRYSTEXXA Details Chronic refractory gout | Approved Quarterly sales | |
LUMAKRAS/LUMYKRAS Details Non-small cell lung carcinoma | PDUFA Approval decision | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details IgG4-related disease | Phase 3 Data readout | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details Neuromuscular disease | Phase 3 Data readout | |
TAVNEOS (Avacopan) (C5aR) Details Hidradenitis suppurativa, Skin disease/disorder | Phase 3 Update | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Autoimmune disease, Cellulite | Phase 3 Initiation | |
HZN-825 Details Idiopathic pulmonary fibrosis | Phase 2b Data readout | |
Bempikibart (ADX-914) Details Alopecia areata | Phase 2 Data readout | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Kidney transplantation, Kidney disease | Phase 2 Data readout | |
Bempikibart (ADX-914) Details Atopic dermatitis | Phase 2 Data readout | |
Dazodalibep (HZN-4920) Details Kidney disease, Lupus nephritis, Autoimmune disease | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Cutaneous lupus erythematosus | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Alopecia areata | Phase 2 Data readout | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details Kidney transplantation, Kidney disease | Phase 2 Data readout | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Arthritis, Genetic disorder, Congenital adrenal hyperplasia, Rheumatoid arthritis, Autoimmune disease | Phase 2 Update | |
TAVNEOS (Avacopan) (C5aR) Details C3 Glomerulopathy, Kidney disease | Phase 2 Update | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Systemic lupus erythematosus | Phase 2 Update | |
HZN-457 Details Chronic refractory gout | Phase 1 Data readout |